Agenus Inc. (AGEN)
NASDAQ: AGEN · Real-Time Price · USD
3.060
-0.150 (-4.67%)
At close: Feb 20, 2026, 4:00 PM EST
3.068
+0.008 (0.27%)
After-hours: Feb 20, 2026, 5:35 PM EST
Agenus Employees
Agenus had 316 employees as of December 31, 2024. The number of employees decreased by 73 or -18.77% compared to the previous year.
Employees
316
Change (1Y)
-73
Growth (1Y)
-18.77%
Revenue / Employee
$338,066
Profits / Employee
-$111,968
Market Cap
104.24M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 316 | -73 | -18.77% |
| Dec 31, 2023 | 389 | -144 | -27.02% |
| Dec 31, 2022 | 533 | 92 | 20.86% |
| Dec 31, 2021 | 441 | 82 | 22.84% |
| Dec 31, 2020 | 359 | 31 | 9.45% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 341 |
| Artiva Biotherapeutics | 106 |
| Fortress Biotech | 101 |
| Korro Bio | 87 |
| Vivani Medical | 37 |
| Cardiff Oncology | 33 |
| Cassava Sciences | 30 |
| Oncolytics Biotech | 28 |
AGEN News
- 1 day ago - Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL - Business Wire
- 11 days ago - Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors - Business Wire
- 22 days ago - Agenus Inc. (AGEN) Discusses Zydus Collaboration, Global Manufacturing Expansion, and Patient Access Initiatives Transcript - Seeking Alpha
- 4 weeks ago - Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab - Business Wire
- 4 weeks ago - Agenus to Host First 2026 Stakeholder Webcast - Business Wire
- 5 weeks ago - Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S. - PRNewsWire
- 5 weeks ago - Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness - Business Wire
- 5 weeks ago - France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas - Business Wire